Tesamorelin is a synthetic research peptide and analog of human growth hormone-releasing hormone (GHRH). Structurally related to naturally occurring GHRH, Tesamorelin has been studied in laboratory research involving pituitary signaling, growth hormone regulation, metabolic pathways, and the growth hormone/insulin-like growth factor-1 (IGF-1) axis.

Tesamorelin research has explored its interaction with GHRH receptors located on pituitary cells. Researchers have investigated the receptor-mediated signaling mechanisms associated with growth hormone secretion and the downstream biological pathways influenced by growth hormone and IGF-1 activity.

Another significant area of Tesamorelin research involves metabolic biology. Laboratory studies have examined GHRH-related signaling in experimental models involving lipid metabolism, body-composition pathways, glucose-related processes, and cellular energy regulation.

Tesamorelin has a molecular weight of approximately 5,135.9 g/mol and can be synthetically produced for controlled research applications. This 10mg formulation is supplied in a nasal research format for laboratory investigation involving GHRH receptor biology, growth hormone signaling, metabolic pathways, and related biochemical processes.